Business Context and Reporting Period
This Form 8-K is filed by Nukkleus Inc. (not T3 Defense Inc.) for the reporting period of September 4, 2024. The filing discloses the creation of new direct financial obligations, the issuance of unregistered equity securities, and significant changes to the company's executive leadership and board of directors.
Key Financial Metrics and Obligations
The filing details two promissory notes issued to X Group Fund of Funds:
- June 2024 Note: Principal amount of $312,500; cash proceeds of $250,000; 12.0% annual interest; due in six months.
- September 2024 Note: Principal amount of $125,000; cash proceeds of $100,000; 12.0% annual interest; due in six months.
- Warrant Issuance: A warrant to acquire 1,200,000 shares of common stock at $0.25 per share was issued as an inducement for the June 2024 Note.
- Conversion Rights: Both notes are convertible into common stock at a price of $0.25 per share.
The filing text does not provide clear values for total revenue, net profit, operating cash flow, or overall liquidity positions beyond the specific proceeds from these notes.
Material Changes
Leadership Changes:
- Resignation: Jamal Khurshid resigned as Chief Executive Officer and Director effective September 4, 2024, following a Settlement Agreement with the Lender and Emil Assentato.
- Appointments: The Board size increased from six to seven. Menachem Shalom was appointed Chief Executive Officer and Director. David Rokach was appointed as a Director.
Debt Structure: The company incurred an additional $125,000 in principal debt obligations in September 2024, increasing its total outstanding principal under these specific notes to $437,500.
Outlook, Risks, and Management Commentary
Management Commentary: The new CEO, Menachem Shalom, brings experience from Motomova Inc., MEA, and Hold Me Ltd. The new Director, David Rokach, is a Senior Investment Manager at the lending entity, X Group Fund of Funds.
Risks and Contingencies:
- High Interest Rates: The new debt carries a 12.0% annual interest rate.
- Dilution Risk: The conversion price of $0.25 per share and the warrant exercise price of $0.25 per share present potential dilution to existing shareholders.
- Liquidity Dependence: The company relies on short-term financing (6-month maturity) to fund operations.
Investor Verification Checklist
- Verify the total outstanding debt load of Nukkleus Inc. beyond the $437,500 disclosed in this filing.
- Confirm the current share count to assess the dilution impact of the 1,200,000 warrant shares and potential note conversions.
- Review the terms of the "Settlement Agreement" mentioned regarding the departure of the former CEO.
- Check for any subsequent filings regarding the company's ability to service the 12% interest on the new notes.